Business Wire

Monrol Announces Investment to Expand its n.c.a. Lu-177 Production Capacity

11.9.2023 19:15:00 EEST | Business Wire | Press release

Share

Eczacıbaşı Monrol Nuclear Products Co. (Monrol), one of the world's leading radiopharmaceutical producers, has decided to invest 35 million Euros to increase its production capacity for non-carrier-added Lutetium-177 (n.c.a. Lu-177) in response to growing global demand for this product.

Monrol, which manufactures radiopharmaceuticals meeting high quality standards at its production facilities, plans to increase its current n.c.a. Lu-177 production capacity through the expansion of existing production lines at the Monrol Gebze facility in Turkey as well as the establishment of a new production facility at the Gebze campus. The expansion project will come into operation gradually and reach full capacity by 2026.

N.c.a. Lu-177 is the radionuclide that forms the basis of targeted radioligand therapy(*), widely used today in the treatment of prostate cancer and neuroendocrine tumors and expected to be used soon to treat other cancers as well.

“Prostate cancer is the most common type of cancer in men after lung cancer, with its incidence increasing rapidly around the world. By 2040, 2.3 million new cases of prostate cancer are predicted annually worldwide. The production capacity increase at our Gebze facility in Turkey, which will comply fully with EU and US quality standards, will meet the increasing global demand for n.c.a. Lu-177. In fact, we aim to make the Gebze production facility a “center of excellence” for the production of theranostic products,” commented Aydin Kucuk, General Manager of Monrol.

(*) Targeted radioligand therapy, is an innovative approach to cancer treatment. Multiple clinical trials are investigating the effects of this treatment approach on various types of cancers across the world.

ENDS

About Monrol
Headquartered in Istanbul, Monrol is a nuclear medicine company leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals, Monrol distributes its world-class radiopharmaceutical products portfolio in global markets. As both a CMO and CDMO, Monrol provides early development support to customers and offers fully integrated services for nimble, lean, virtual companies taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment through a portfolio of radiopharmaceutical products that it distributes to more than 60 countries around the globe. To learn more, visit www.monrol.com and LinkedIn.

About n.c.a. Lutetium-177
Lutetium-177 n.c.a. is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a. enables treatment options that have the potential today to improve treatment outcomes for certain cancer patients and may soon offer improved treatment options for others, thanks to ongoing clinical development. The unique properties of Lu-177 n.c.a. make it a desirable radioisotope for peptide receptor radionuclide therapy (PRRT) used to treat certain cancers like Neuro Endocrine Tumors (NET) and Prostate cancer. Monrol n.c.a. Lutetium-177 DMF has been listed by the FDA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information please contact:

Monrol
Aydın Küçük
General Manager
monrol@monrol.com

Media Enquiries
Alkim Aydın
Marketing Manager
alkim.aydin@monrol.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Textron Aviation Launches Donation Campaign to Support 2026 Special Olympics Airlift; Continues Nationwide Call for Volunteer Doves2.3.2026 18:00:00 EET | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of a donation campaign benefitting Special Olympics in support of the 2026 Special Olympics Airlift, a nationwide effort that brings athletes and coaches to the Special Olympics USA Games through the generosity of volunteer pilots, aircraft owners and operators known as Doves. Financial contributions go directly to the Special Olympics, a 501(c)(3) charitable organization. New for the 2026 event, the donation campaign serves a vital role in ensuring each delegation has what it needs for a smooth and welcoming travel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302196418/en/ Textron Aviation launches donation campaign to support 2026 Special Olympics Airlift; continues nationwide call for volunteer Doves (Photo credit: Textron Aviation). “This campaign reflects the spirit of unity and generosity that defines the Special Olym

Forrester Announces The Agenda For Its 2026 CX Events To Help Address The Challenges AI Can’t Handle Alone2.3.2026 16:30:00 EET | Press release

Forrester (Nasdaq: FORR) today announced the agenda for its global customer experience (CX) event series: CX Summit EMEA, being held in Amsterdam, June 8–10, 2026; CX Forum East, being held in New York City, June 16–17, 2026; and CX Forum West, being held in San Francisco, June 29–30, 2026. Today, CX, marketing, and digital business leaders are under mounting pressure to leverage AI to architect smarter end-to-end customer journeys, automate service, operationalize AI agents, and deliver true personalization at scale — all while consumer trust is at an all-time low. While AI is promising to raise the bar for speed and efficiency, beneath every customer experience is a foundation that AI alone can’t build. To forge trust, organizations need to embed human creativity, context, customer identity, and quality data into every customer interaction. This year’s theme, “Build The Experience AI Can’t,” will empower leaders to shift from doing more with AI to creating better experiences powered

Incode First to Achieve iBeta’s Highest Level of Independent Identity Security Testing on Both iOS and Android With 0% Error Rate2.3.2026 16:00:00 EET | Press release

Incode Technologies, Inc., the global leader in identity security and fraud prevention, today announced that iBeta PAD testing confirmed Incode’s face liveness technology achieves Level 3 Presentation Attack Detection (PAD) conformance under ISO/IEC 30107-3. "We are the first company to independently achieve iBeta Level 3 conformance on both iOS and Android – with zero errors and without adding friction to users," said Ricardo Amper, Founder & CEO at Incode. "That combination matters. It proves we can meet the highest bar for liveness assurance while keeping onboarding fast and easy, even in regulated and high-risk environments." Face liveness technology is used in digital onboarding and authentication to confirm a real, live person is present during a selfie capture – not a printed photo, video replay, mask, or other spoofing attempt. It enables organizations to defend remote identity verification flows against account takeovers, synthetic identity fraud, and impersonation scams. Inco

Safe Software Expands its FME Platform with MCP2.3.2026 16:00:00 EET | Press release

Today, Safe Software (Safe), the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, announced that Model Context Protocol (MCP) capabilities are coming soon to its FME Platform. This update expands what organizations can do with their existing data and workflows. As organizations move AI from experimentation to production they face growing challenges around context management, interoperability, and security. MCP provides a standardized way for AI, agents and other systems to interact with external systems, such as databases, internal tools, and APIs, without hard-coding integrations. “Adding MCP to the FME Platform is an important step in our All-Data, Any-AI mission,” said Don Murray, CEO of Safe Software. “With MCP, our customers can adopt new AI models without rebuilding integrations. By extending FME Flow with MCP Server capabilities, we’re giving organizations a future-proof way to let AI securely work with the systems the

Smartly Announces Amazon DSP Integration to Extend Intelligent Creative and Campaign Management to Connected TV2.3.2026 15:59:00 EET | Press release

Smartly announced today an integration with Amazon DSP that enables advertisers to extend their Smartly video campaigns to Amazon's premium CTV inventory, including Prime Video and Fire TV, and third-party publisher inventory. The new integration addresses growing market demand as CTV investment accelerates, with nearly 70% of marketers1 planning to increase streaming budgets over the next year while seeking more personalization, agility, and measurable outcomes from their campaigns. The Smartly integration with Amazon DSP is available globally, with additional features rolling out later in 2026. The integration brings streaming TV activation into advertisers' existing workflows in Smartly through three core capabilities. Smartly enables AI-powered creative optimization and personalization from social channels to streaming. The new capability eliminates the creative production bottlenecks that prevent many advertisers from activating CTV campaigns. Advertisers can then create, manage,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye